Opioid and other drug use and drug-related mortality as indicators of Hepatitis C and Human Immunodeficiency Virus in Oklahoma

被引:0
|
作者
Wendelboe, Aaron M. [1 ]
Naqvi, Ozair H. [1 ]
Williams, Mary [1 ]
Hollen, Heather [1 ]
McGrew, Kaitlin [2 ]
Li, Peng [2 ]
Harris, Terrainia [2 ]
Chou, Ann F. [3 ]
机构
[1] Univ Oklahoma, Hudson Coll Publ Hlth, Dept Biostat & Epidemiol, Hlth Sci Ctr, Oklahoma City, OK 73104 USA
[2] Oklahoma State Dept Hlth Sexual Hlth & Harm Reduct, Oklahoma City, OK USA
[3] Univ Oklahoma, Hlth Sci Ctr, Coll Med, Dept Family & Prevent Med, Oklahoma City, OK USA
来源
PLOS ONE | 2024年 / 19卷 / 05期
关键词
UNITED-STATES; INJECT DRUGS; HIV; VULNERABILITY; OXYMORPHONE; EPIDEMIC; INDIANA; HCV;
D O I
10.1371/journal.pone.0301442
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objectives Outbreaks of injection drug use (IDU)-associated infections have become major public health concerns in the era of the opioid epidemic. This study aimed to (1) identify county-level characteristics associated with acute HCV infection and newly diagnosed IDU-associated HIV in Oklahoma and (2) develop a vulnerability index using these metrics.Methods This study employs a county-level ecological design to examine those diagnosed with acute or chronic HCV or newly diagnosed IDU-associated HIV. Poisson regression was used to estimate the association between indicators and the number of new infections in each county. Primary outcomes were acute HCV and newly diagnosed IDU-associated HIV. A sensitivity analysis included all HCV (acute and chronic) cases. Three models were run using variations of these outcomes. Stepwise backward Poisson regression predicted new infection rates and 95% confidence intervals for each county from the final multivariable model, which served as the metric for vulnerability scores.Results Predictors for HIV-IDU cases and acute HCV cases differed. The percentage of the county population aged 18-24 years with less than a high school education and population density were predictive of new HIV-IDU cases, whereas the percentage of the population that was male, white, Pacific Islander, two or more races, and people aged 18-24 years with less than a high school education were predictors of acute HCV infection. Counties with the highest predicted rates of HIV-IDU tended to be located in central Oklahoma and have higher population density than the counties with the highest predicted rates of acute HCV infection.Conclusions There is high variability in county-level factors predictive of new IDU-associated HIV infection and acute HCV infection, suggesting that different public health interventions need to be tailored to these two case populations.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs
    Grebely, Jason
    Collins, Alexandra B.
    Artenie, Andreea Adelina
    Sutherland, Rachel
    Meyer, Jaimie P.
    Barocas, Joshua A.
    Falade-Nwulia, Oluwaseun
    Cepeda, Javier A.
    Cunningham, Evan B.
    Hajarizadeh, Behzad
    Lafferty, Lise
    Lazarus, Jeffrey, V
    Bonn, Matthew
    Marshall, Alison D.
    Treloar, Carla
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2021, 96
  • [32] HUMAN IMMUNODEFICIENCY VIRUS AND HEPATITIS-DELTA-VIRUS IN INTRAVENOUS DRUG-ADDICTS
    LAKEBAKAAR, G
    BEIDAS, S
    HEPATOLOGY, 1988, 8 (05) : 1329 - 1329
  • [33] The impact of behavioural changes on the prevalence of human immunodeficiency virus and hepatitis C among injecting drug users
    Murray, JM
    Law, MG
    Gao, ZH
    Kaldor, JM
    INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2003, 32 (05) : 708 - 714
  • [34] Commentary: Modelling and understanding differences in human immunodeficiency and hepatitis C virus epidemiology in injection drug users
    Zwahlen, M
    Vlahov, D
    INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2003, 32 (05) : 715 - 716
  • [35] Seroprevalence for the human immunodeficiency virus, hepatitis B and C in injecting drug users. Uruguay, 2003
    Luz Osimani, Maria
    Vazquez Pedrouzo, Rodolfo
    Chiparelli, Hector
    Guchin, Monica
    Latorre, Laura
    Garibotto, Giorgina
    Gherardi Perez, Alejandro
    Vidal, Jahel
    REVISTA MEDICA DEL URUGUAY, 2005, 21 (03): : 207 - 214
  • [36] Co-infection of human immunodeficiency virus, hepatitis C and hepatitis B virus among injection drug users in Drop in centers
    Javadi, Abbasali
    Ataei, Behrooz
    Kassaian, Nazila
    Nokhodian, Zary
    Yaran, Majid
    JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2014, 19 : S17 - S21
  • [37] Efficacy vs impact of human immunodeficiency virus related drug therapies
    Zierler, S
    EPIDEMIOLOGY, 1998, 9 (06) : 590 - 593
  • [38] Hepatitis C Virus Infection among Injection Drug Users with and without Human Immunodeficiency Virus Co-Infection
    Hsieh, Meng-Hsuan
    Tsai, Jih-Jin
    Hsieh, Ming-Yen
    Huang, Chung-Feng
    Yeh, Ming-Lun
    Yang, Jeng-Fu
    Chang, Ko
    Lin, Wei-Ru
    Lin, Chun-Yu
    Chen, Tun-Chieh
    Huang, Jee-Fu
    Dai, Chia-Yen
    Yu, Ming-Lung
    Chuang, Wan-Long
    PLOS ONE, 2014, 9 (04):
  • [39] Management and treatment of injection drug users with hepatitis C virus (HCV) infection and HCV/human immunodeficiency virus coinfection
    Dore, GJ
    Thomas, DL
    SEMINARS IN LIVER DISEASE, 2005, 25 (01) : 18 - 32
  • [40] Impact of human immunodeficiency virus (HIV) infection on hepatitis C virus (HCV) persistence among illicit drug users
    Grebely, Jason
    Raffa, Jesse D.
    Lai, Calvin
    Krajden, Mel
    Conway, Brian
    Tyndall, Mark W.
    HEPATOLOGY, 2006, 44 (04) : 272A - 272A